Table of Contents Abbreviations ........................................................................................................................................................................................................... 5 Executive Summary .................................................................................................................................................................................................. 9 Vaccines where both MNCs and Indian companies hold marketing registrations in India ........................................................................................................................... 10 Vaccines where only MNCs are currently marketing products in India ........................................................................................................................................................ 12 Vaccines yet to be globally launched ............................................................................................................................................................................................................ 13 Summary Table ............................................................................................................................................................................................................................................. 14 Approach and methodology .................................................................................................................................................................................. 15 Pneumococcal Vaccine .......................................................................................................................................................................................... 19 Overview ....................................................................................................................................................................................................................................................... 20 Marketed products – technical overview ..................................................................................................................................................................................................... 20 Marketed products – commercial overview ................................................................................................................................................................................................. 21 Pipeline Review ............................................................................................................................................................................................................................................. 22 Rotavirus Vaccine: .................................................................................................................................................................................................. 31 Overview ....................................................................................................................................................................................................................................................... 32 Marketed products – technical overview ..................................................................................................................................................................................................... 32 Marketed products – commercial overview ................................................................................................................................................................................................. 33 Pipeline review .............................................................................................................................................................................................................................................. 34 DTwP-HepB-Hib Pentavalent Vaccine .................................................................................................................................................................... 41 Overview ....................................................................................................................................................................................................................................................... 42 Currently marketed products- Technical Review: ......................................................................................................................................................................................... 43 Currently marketed products- Commercial Review: ..................................................................................................................................................................................... 43 Pipeline Review: ............................................................................................................................................................................................................................................ 45 1 | P a g e Typhoid Vaccine: .................................................................................................................................................................................................... 52 Overview ....................................................................................................................................................................................................................................................... 54 Marketed Products- Technical Overview ...................................................................................................................................................................................................... 54 Marketed Products - Commercial Overview ................................................................................................................................................................................................. 55 Pipeline Review ............................................................................................................................................................................................................................................. 56 Japanese Encephalitis Vaccine ............................................................................................................................................................................... 63 Overview ....................................................................................................................................................................................................................................................... 64 Currently marketed products - Technical Overview ..................................................................................................................................................................................... 64 Currently marketed products- Commercial Overview .................................................................................................................................................................................. 66 Pipeline Review ............................................................................................................................................................................................................................................. 68 Human Papilloma Virus Vaccine (HPV) .................................................................................................................................................................. 77 Overview ....................................................................................................................................................................................................................................................... 78 Currently marketed products – technical overview ...................................................................................................................................................................................... 78 Currently marketed products – commercial overview ................................................................................................................................................................................. 80 Pipeline Review ............................................................................................................................................................................................................................................. 81 Inactivated Polio Vaccine (IPV) .............................................................................................................................................................................. 87 Overview ....................................................................................................................................................................................................................................................... 88 Currently marketed products – technical overview ...................................................................................................................................................................................... 88 Currently marketed products –commercial overview .................................................................................................................................................................................